Schwaneke Jeffrey A.'s Form 4/A amendment
Amendedagilon health, inc.AGL · filed Apr 3, 2025
- Accession no.
- 0001628280-25-016684
- Filed
- Apr 3, 2025
- Trade date
- Nov 29, 2023-Apr 1, 2025
- Filing delay
- 491 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Nov 30, 2023
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $250.2K. It was filed 491 days after the trade.
This amendment replaces 0001628280-23-040361 (filed Nov 30, 2023).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schwaneke Jeffrey A.CIK 0001446919 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 29, 2023 | Common Stock | PPurchaseAcquired | +22,300 | $11.22F1 | +$250,206 | 22,300 | Indirect | |
| Apr 1, 2025 | Common Stock | AGrant or awardAcquired | +428,922 | $0.00 | $0 | 1,130,552 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 1, 2025 | Common Stock | AGrant or awardAcquired | +673,077 | $0.00 | $0 | 673,077 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $11.12 to $11.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
Referenced by the price of 1 transaction in Table I.
- F2
This transaction was originally reported in November 2023 and is hereby amended to clarify that the shares were purchased by and are held in the Schwaneke Family Joint Spousal Trust.
- F3
Restricted stock units that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.
- F4
Includes Performance Stock Units which may become vested subject to attainment (based on 40 trading day average closing price, exceeding twice the closing price of the Company's stock price on date of grant) and within three years from grant date.
- F5
Includes restricted stock units.
- F6
Options that vest in three equal installments on each anniversary of April 1, 2025, subject to continued employment.